Participant flow16

How many started, completed or left each group, period by period.

1 to 16 of 16

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	164
Overall Study	STARTED	Ramelteon SL 0.1 mg	164
Overall Study	STARTED	Ramelteon SL 0.4 mg	160
Overall Study	STARTED	Ramelteon SL 0.8 mg	154
Overall Study	Safety Analysis Set: Received Treatment	Placebo	163
Overall Study	Safety Analysis Set: Received Treatment	Ramelteon SL 0.1 mg	164
Overall Study	Safety Analysis Set: Received Treatment	Ramelteon SL 0.4 mg	159
Overall Study	Safety Analysis Set: Received Treatment	Ramelteon SL 0.8 mg	154
Overall Study	COMPLETED	Placebo	62
Overall Study	COMPLETED	Ramelteon SL 0.1 mg	60
Overall Study	COMPLETED	Ramelteon SL 0.4 mg	58
Overall Study	COMPLETED	Ramelteon SL 0.8 mg	45
Overall Study	NOT COMPLETED	Placebo	102
Overall Study	NOT COMPLETED	Ramelteon SL 0.1 mg	104
Overall Study	NOT COMPLETED	Ramelteon SL 0.4 mg	102
Overall Study	NOT COMPLETED	Ramelteon SL 0.8 mg	109

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01467713/flow